Emcure Pharmaceuticals reported a 24.7% year-on-year (y-o-y) increase in net profit to Rs 251 crore, and a 13.4% rise in revenues to Rs 2,270 crore for the quarter ending in September.
The company’s Ebitda margins stood at 19.3% amounting to Rs 439 crore, representing a 15.2% y-o-y growth. Emcure’s domestic business sales reached Rs 1,031 crore, up 10.6%, while international business sales increased by 15.8% to Rs 1,238 crore.
The domestic business experienced growth across all key therapy areas, bolstered by new initiatives. The company is expanding its domestic portfolio and strengthening its team.
Emcure also announced a strategic partnership with Novo Nordisk to launch Poviztra, a biological injectable semaglutide, in India. As part of this agreement, Emcure will serve as the exclusive distributor responsible for the commercialisation and promotion of Poviztra, which is indicated for chronic weight management and for reducing the risk of major adverse cardiovascular events in individuals with overweight or obesity.
The international business exhibited growth of 16%, with Europe growing by 23% driven by new product launches. Growth in Canada was reported at 18%.
Satish Mehta, CEO and managing director of Emcure Pharmaceuticals, stated, “The second quarter saw strong performance across all our businesses. We continue to enhance our portfolio in all our focus markets through in-licensing and in-house developments. Our partnership with Novo Nordisk positions us well in the rapidly growing obesity segment and gives us an early entry to shape the market.”